Baiju R. Shah serves as a Senior Advisor to FasterCures, a Milken Institute center through which he supports innovative biomedical financing platforms. He is also the Senior Fellow for Innovation and an Impact Investment board member at The Cleveland Foundation, a $2.6 billion organization, where he develops strategic initiatives to grow the region's tech economy. Shah was the CEO of BioMotiv and co-leader of The Harrington Project for Discovery & Development, a $380 million drug development initiative. The company established strategic partnerships with Takeda, Biogen, Bristol-Myers Squibb, AstraZeneca, and Johnson & Johnson. Prior to that, he was CEO and co-founder of BioEnterprise, an accelerator formed with Cleveland Clinic, Case Western Reserve University, and University Hospitals of Cleveland. Shah is a Director of Invacare (NYSE) and Athersys (NASDAQ). He began his career as a consultant with McKinsey & Company. Shah has been named an Ernst & Young Entrepreneur of the Year and recognized as one of Cleveland's influential leaders. He is a graduate of Harvard Law School and Yale University.